About XOMA Corporation
XOMA Corporation is a publicly listed company based in Berkeley (United States) founded in 1981, and was acquired by Ligand Pharmaceuticals in July 2026. Antibody-based therapeutics are developed for endocrine and metabolic diseases. The company has 13 employees. XOMA Corporation has completed 6 acquisitions, including Generation Bio, Kinnate Biopharma and Lava Therapeutics. XOMA Corporation offers products and services including Royalty Acquisition Service, Phage Display Platform, Ebopiprant, and Anti-prolactin Antibody. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Endocrine disorders. Its legal entity is XOMA Royalty Corporation. Its competitors include Neurocrine, Crinetics and MacroGenics; 3 of its 3 listed competitors have raised funding.
Company details
XOMA Corporation was founded in 1981 and is headquartered in Berkeley, United States. Operations focus on biotechnology, with antibody-based therapeutics developed for endocrine and metabolic disorders. The pipeline features XOMA-358, a drug candidate in Phase 2 trials for congenital hyperinsulinism and post-bariatric surgery hyperinsulinism. Development efforts target unmet needs in these therapeutic areas through innovative antibody engineering.
- Headquarters Berkeley, United States
- Employees 13
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website xoma.com
- Social LinkedIn X
- Acquired by Ligand Pharmaceuticals (Jul 2026)
- Legal Name Xoma Royalty Corporation
- Annual Revenue$28.49 M (USD)498.72as on Dec 31, 2024
- Net Profit-$13.82 M (USD)66.15as on Dec 31, 2024
- EBITDA-$39.76 M (USD)-89.44as on Dec 31, 2024
- Latest Funding Round$1.9M (USD), Post-IPO
Oct 2020
- InvestorsSVB
& 2 more
- Employee Count13
- Investments & AcquisitionsGeneration Bio
& 5 more
- Acquired byLigand Pharmaceuticals
(Jul 2026)
Products & Services of XOMA Corporation
XOMA Corporation offers a comprehensive portfolio of products and services, including Royalty Acquisition Service, Phage Display Platform, Ebopiprant, and Anti-prolactin Antibody.
Service for acquiring rights to biotech royalties and milestones.
Platform offering phage display technology for drug development.
Therapeutic asset for potential royalty and milestone payments.
Antibody asset available for licensing in drug candidates.
Funding Insights of XOMA Corporation
- Total Rounds 2
- Last Round Post-IPO — $1.9M
- First Round $20M
(May 2018)
- Investors Count 2
All 2 funding rounds of XOMA Corporation with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in XOMA Corporation
XOMA Corporation has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include SVB, Rezolute and Ligand Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | rezolutebio.com | Denver, United States | |
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States | |
Pharmaceutical drugs are manufactured and developed in the United States. | 1987 | ligand.com | San Diego, United States |
Investor details for XOMA Corporation
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of XOMA Corporation
23 people are tracked at XOMA Corporation (11 in leadership, 7 in board & advisors, 5 in team); the tracked headcount is 13.
| Name | Role | Group |
|---|---|---|
James R. Neal | CEO | Leadership |
Al Dadson | Vice President, Manufacturing Operations & Facilities Engineering | Leadership |
Jessica Holden | Group CFO | Leadership |
Lisa Christensen | Executive Assistant to the CEO | Leadership |
Fred Kurland | Vice President, Finance and Chief Financial Officer | Leadership |
Christine Theriault, CPA | Vice President, Corporate Controller | Leadership |
Christopher Baldwin | Vice President, Legal | Leadership |
Nicholas A. Cole | Vice President, Finance & Acquisitions | Leadership |
Brad Sitko | Chief Investment Officer | Leadership |
Thomas Burns | Senior Vice President, Finance and CFO | Leadership |
Peter Rehnquist | Director Corporate Development | Leadership |
Barbara Kosacz | Director | Board & advisors |
Joseph M. Limber | Director | Board & advisors |
Matthew Perry | Director | Board & advisors |
Jack L. Wyszomierski | Director | Board & advisors |
Natasha Hernday | Director | Board & advisors |
Heather L. Franklin | Director | Board & advisors |
Owen Hughes | Executive Chairman | Board & advisors |
Juliane Snowden | Investor Relations | Team |
Tim Ditico | Senior Accountant | Team |
3 more people are available in the full profile.
Complete people profiles for XOMA Corporation
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of XOMA Corporation
XOMA Corporation is a publicly listed company on the NASDAQ with ticker symbol XOMA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Nov 2012
- Listed onNASDAQ: XOMA
- Listed entityXOMA Royalty Corporation
- Exchange sectorHealth technology
- ISINUS98419J2069
- Share price$41.89 (+1.45% on the day) · 2026-05-11
- Market capitalisation$508.1M
- Price to earnings28.8
- EPS (diluted, trailing year)$1.45
- Volume (last session)111,716
- Analyst consensusBuy
Financials of XOMA Corporation
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $28.5M | -$13.8M | -$39.8M |
| 2023 | $4.8M | -$40.8M | -$21.0M |
| 2022 | $6.0M | -$17.1M | -$17.1M |
| 2021 | $38.2M | $12.3M | $17.7M |
| 2020 | $29.4M | $8.9M | $12.6M |
Detailed financial statements for XOMA Corporation
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by XOMA Corporation
XOMA Corporation has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include Generation Bio, Kinnate Biopharma and Lava Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gene therapies for rare liver and eye diseases are developed. | generationbio.com | Cambridge, United States | 2016 | Dec 2025 | •••• | |
Cytokine-based immunotherapies for cancer treatment are developed. | muraloncology.com | Waltham, United States | 2023 | Aug 2025 | •••• | |
Gamma delta T-cell engagers are developed for cancer treatment. | lavatherapeutics.com | 2016 | Aug 2025 | •••• | ||
XOMA Royalty is engaged in biotech royalty aggregation activities. | turnstonebio.com | San Diego, United States | 2015 | Jun 2025 | •••• | |
Treatments for pulmonary hypertension are developed using kinase technology. | pulmokine.net | Rensselaer, United States | 2007 | Dec 2024 | •••• | |
Small molecule therapeutics for cancer treatment are developed. | kinnate.com | San Diego, United States | 2018 | Feb 2024 | •••• |
Complete acquisition details for XOMA Corporation
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of XOMA Corporation
11 dated milestones of XOMA Corporation across 45 years, from founding to its latest funding, stage changes and deals.
- Founded XOMA Corporation is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $20.0M.
- Funding Latest funding round, Post-IPO, of $1.9M.
- Acquisition Acquires Kinnate Biopharma.
- Acquisition Acquires Pulmokine.
- Acquisition Acquires XOMA Royalty.
- Acquisition Acquires Lava Therapeutics.
- Acquisition Acquires Mural Oncology.
- Acquisition Acquires Generation Bio.
- Exit Acquired by Ligand Pharmaceuticals.
Competitors of XOMA Corporation
XOMA Corporation has 3 listed competitors in our database, 3 of them funded. They include Neurocrine, Crinetics and MacroGenics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| crinetics.com | 2008 | San Diego, United States | $103.5M | 120 | Developer of therapies for the treatment of endocrine-related diseases and cancers | |
| macrogenics.com | 2000 | Rockville, United States | $126.02M | 339 | A biopharmaceutical company focused on cancer therapeutics development. |
Detailed competitors of XOMA Corporation
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of XOMA Corporation
The website of XOMA Corporation (xoma.com) receives about 8K visits a month and ranks #3,718,828 among all websites worldwide, #4,764 in Biotechnology and Pharmaceuticals.
- Monthly visits8K
▲ 43.5% vs previous month
- Unique visitors2.6K
per month
- Global rank#3,718,828
among all websites
- Category rank#4,764
Health · Biotechnology and Pharmaceuticals
- Bounce rate49%
- Pages per visit1.4
- Average visit12 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with XOMA Corporation. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| canfite.com | 100% | 4.5K | #4,278,330 | View details | |
| siga.com | 100% | 8.4K | #3,215,987 | View details | |
| trimeris.com | 100% | View details | |||
| plexxikon.com | 99% | View details | |||
| kurmapartners.com | 33% | 4.2K | #4,297,569 | View details |
Top companies in Metabolic Diseases
3 companies that operate in the same segment as XOMA Corporation (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xoma Corporation
Complete news archive for XOMA Corporation
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about XOMA Corporation
XOMA Corporation was founded in 1981 and raised its 1st funding round 37 years after it was founded.
XOMA Corporation is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
XOMA Corporation has 13 employees.
Annual revenue of XOMA Corporation is $28.49M as on Dec 31, 2024.
XOMA Corporation was founded in 1981 and is headquartered in Berkeley, United States. Operations focus on biotechnology, with antibody-based therapeutics developed for endocrine and metabolic disorders. The pipeline features XOMA-358, a drug candidate in Phase 2 trials for congenital hyperinsulinism and post-bariatric surgery hyperinsulinism. Development efforts target unmet needs in these therapeutic areas through innovative antibody engineering.
XOMA Corporation's top competitors include Crinetics, Neurocrine and MacroGenics.
XOMA Corporation offers Royalty Acquisition Service, Phage Display Platform, Ebopiprant, and Anti-prolactin Antibody.
Yes, XOMA Corporation is publicly traded on NASDAQ under the ticker symbol XOMA.
XOMA Corporation has made 6 acquisitions, including Generation Bio, Kinnate Biopharma, and Lava Therapeutics.
XOMA Corporation has 3 investors. Key investors include SVB, Rezolute, and Ligand Pharmaceuticals.
XOMA Corporation operates through Xoma Royalty Corporation.
Yes. XOMA Corporation was acquired by Ligand Pharmaceuticals in July 2026.